pdf   xlsx method abbreviations

mNSCLC - L1 - PDL1 positive, durvalumab plus tremelimumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.85 [0.61, 1.18]< 10%1 study (1/-)83.6 %NAnot evaluable crucial-
progression or deaths (PFS) 1.05 [0.72, 1.53]< 10%1 study (1/-)40.0 %NAnot evaluable important-
objective responses (ORR) 0.87 [0.55, 1.37]> 10%1 study (1/-)27.3 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.43 [0.15, 1.24]< 10%1 study (1/-)94.2 %NAnot evaluable non important-
AE (grade 3-4) 0.86 [0.56, 1.35]< 10%1 study (1/-)74.0 %NAnot evaluable non important-
AE leading to death (grade 5) 3.45 [1.24, 9.59]< 10%1 study (1/-)0.9 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 1.63 [0.91, 2.93]< 10%1 study (1/-)5.2 %NAnot evaluable non important-
SAE (any grade) 1.93 [1.22, 3.04]< 10%1 study (1/-)0.2 %NAnot evaluable non important-
STRAE (any grade) 1.05 [0.59, 1.87]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
TRAE (any grade) 0.17 [0.09, 0.30]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE (grade 3-4) 0.36 [0.22, 0.60]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.94 [0.06, 15.13]< 10%1 study (1/-)51.8 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 1.04 [0.54, 2.03]< 10%1 study (1/-)45.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons